Tag - PALI

Palisade Bio Logo

JD Finley named interim CEO of Palisade Bio

Palisade Bio (NASDAQ:PALI) named JD Finley, CFO, as interim CEO, replacing Thomas Hallam, Ph.D., effective Oct. 10. In a statement, James Neal, chairman of Palisade, said Dr. Hallam was “instrumental in the development...

Palisade Bio Logo

Maxim starts Palisade Bio at buy; PT $7

Maxim Group initiated coverage of Palisade Bio (NASDAQ:PALI) with a “buy” rating and price target of $7. The stock closed at $2.73 on Aug. 30. Palisade Bio is a clinical-stage company developing LB1148, an oral...